Beam Therapeutics Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
6
Neutral
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
BEAM
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ currently unprofitable (-57% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $51.20 (+66.8%)
15 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
BEAM
JNJ
—
Trailing P/E
26.3×
-7.0×
Forward P/E
17.9×
-57.2%
Profit Margin
21.8%
-193.1%
Gross Margin
68.0%
-8.1%
ROE
26.4%
279.5%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
2.19
Beta
0.33
—
Price / Book
—
$3.2B
Market Cap
$546.9B
$15 – $36
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →